Adam Lerner MD

Hematologic Oncology

Professor of Medicine, Boston University School of Medicine

830 Harrison Ave 3rd FLMoakley HematologyoncologyBoston, MA 02118
Phone+1 617-638-6428
Fax+1 617-638-5756

Dr. Lerner is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lerner's full profile Already have an account?

Summary

Dr. Adam Lerner is an oncologist in Boston, MA. He received his medical degree from Yale University School of Medicine and has been in practice 34 years, primarily at Boston University and Boston Medical Center. He has carried out translational research on cyclic nucleotide phosphodiesterase inhibitors as well as on a focal adhesion complex adapter protein, BCAR3/AND-34. He specializes in hematologic oncology, cutaneous oncology and soft tissue sarcomas.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1988 - 1991
Boston University Medical CenterResidency, Pathology-Anatomic and Clinical, 1986 - 1987
Boston University Medical CenterResidency, Internal Medicine, 1983 - 1986
Yale School of MedicineClass of 1983
Amherst CollegeA.B., Biology, 1979

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MA State Medical License 1986 - 2027
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

DOD Breast Cancer Idea Award 2001
Career Development Award American Society of Clinical Oncology, 1998
Leukemia Society of America Translational Research Award 1997

Clinical Trials

Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
TERMINATED
PHASE1
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
COMPLETED
PHASE2
Everolimus in Treating Cutaneous T-cell Lymphoma
TERMINATED
PHASE2

Publications & Presentations

PubMed

When ICAN(S) Becomes ICAN'T: Clinician and Staff Perspectives on In-Hospital Neurotoxicity Grading.
Grace M Ferri, Allison Frank, Daniel Li, Pria Anand, Maya Abdallah
Clinical Lymphoma, Myeloma & Leukemia. 2026-01-01
1 citations
Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis.
Maya Abdallah, Frances Arters, Jasmine Patel, Camille Edwards, Adam Lerner
Blood Advances. 2024-12-10
1 citations
A prospective, single-center, randomized phase 2 trial of etoposide in severe COVID-19.
Meredith Halpin, Adam Lerner, Manish Sagar, Praveen Govender, Bhavesh Shah
Medrxiv. 2023-06-06

Journal Articles

AND-34/BCAR3 augments the ability of p130Cas to bind the Src SH3 domain in a BCAR3-p130Cas complex-dependent manner
Makkinje A, VandenBorre P, Near RI, Patel P and Lerner A, J. Biol. Chem, 1/1/2012
Primary cutaneous CD56 positive lymphoma: a diagnostic conundrum in an unusual case of lymphoma
Schieke SM, Sharaf M, Lerner A, Runger T, Mahalingam M, J. Cutan. Pathol, 1/1/2012
Complete response of metastatic hidradenocarcinoma to capecitabine
Lerner A, Beckford A, Ugent S, Goldberg L, Jalisi S and Demierre MF, Archives of Derm, 1/1/2011

Books/Book Chapters

Goldman’s Cecil Medicine
Chapter: Primary and metastatic malignant bone lesions
Lerner A and Antman KEdition 24th,2011
ACP Medicine
Chapter: Sarcomas of soft tissue and bone
Lerner A and Antman KB C Decker Publishers2011
Cyclic Nucleotide Phosphodiesterases in Health and Disease
Chapter: Role of Phosphodiesterases in apoptosis
Page 559 - 582Lerner A, Moon E and Tiwari SEditors: J Beavo, S Francis and M Houslay.CRC Press2006

Abstracts/Posters

Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact
Adam Lerner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019